Compare UAN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAN | SLN |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2008 | 2010 |
| Metric | UAN | SLN |
|---|---|---|
| Price | $126.17 | $19.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $33.00 |
| AVG Volume (30 Days) | 14.7K | ★ 3.9M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 8.42% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 12.06 | N/A |
| Revenue | ★ $606,038,000.00 | $559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $130.93 |
| P/E Ratio | $10.45 | ★ N/A |
| Revenue Growth | ★ 15.36 | N/A |
| 52 Week Low | $91.44 | $4.19 |
| 52 Week High | $139.50 | $19.69 |
| Indicator | UAN | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 79.34 |
| Support Level | $121.91 | $4.97 |
| Resistance Level | $130.40 | N/A |
| Average True Range (ATR) | 3.04 | 0.45 |
| MACD | 0.02 | 1.28 |
| Stochastic Oscillator | 25.67 | 99.86 |
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.